(Total Views: 640)
Posted On: 06/18/2025 9:56:03 PM
Post# of 154593
Canonical immune checkpoint response
2019 & a study includes Dr. RP:
https://aacrjournals.org/cancerres/article/79...er-and-Its
___
Google:
The term "canonical immune checkpoint" most often refers to the PD-1/PD-L1 pathway and the CTLA-4 pathway, which are the most well-studied and targeted immune checkpoint pathways in cancer immunotherapy.
___
Google:
Combination Therapy: CTLA-4 inhibitors are often used in combination with other immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) or other cancer therapies to improve efficacy.
___
The main CTLA-4 inhibitors used in clinical treatment are Ipilimumab (Yervoy) and Tremelimumab (Imjudo).
Ipilimumab was the first FDA-approved immune checkpoint inhibitor, initially for advanced melanoma in 2011. It works by blocking the interaction of CTLA-4 with CD80/CD86, thereby enhancing T-cell activation.
Tremelimumab, also a monoclonal antibody that targets CTLA-4, works by inhibiting the binding of CTLA-4 to CD80/CD86, thus blocking the CTLA-4 pathway and enhancing immune responses against tumor cells. It was approved in October 2022
2019 & a study includes Dr. RP:
https://aacrjournals.org/cancerres/article/79...er-and-Its
___
Google:
The term "canonical immune checkpoint" most often refers to the PD-1/PD-L1 pathway and the CTLA-4 pathway, which are the most well-studied and targeted immune checkpoint pathways in cancer immunotherapy.
___
Google:
Combination Therapy: CTLA-4 inhibitors are often used in combination with other immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) or other cancer therapies to improve efficacy.
___
The main CTLA-4 inhibitors used in clinical treatment are Ipilimumab (Yervoy) and Tremelimumab (Imjudo).
Ipilimumab was the first FDA-approved immune checkpoint inhibitor, initially for advanced melanoma in 2011. It works by blocking the interaction of CTLA-4 with CD80/CD86, thereby enhancing T-cell activation.
Tremelimumab, also a monoclonal antibody that targets CTLA-4, works by inhibiting the binding of CTLA-4 to CD80/CD86, thus blocking the CTLA-4 pathway and enhancing immune responses against tumor cells. It was approved in October 2022
(4)
(0)
